– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement – – Strong activity observed across ESA-refractory and ESA-intolerant patients, and across mutation and morphology subtypes – – Favorable safety profile with no treatment-related serious...
Hence then, the article about halia therapeutics announces positive phase 2a data for ofirnoflast in lower risk mds at ash 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025 )
Also on site :
- Cyberattack hits Canvas system used by thousands of schools as finals loom
- Philadelphia Soccer 2026 otvára akreditácie médií a registráciu fanúšikov na festival fanúšikov FIFA Fan Festival™ vo Philadelphii
- China Innovative Drug NHWD-870 Receives Breakthrough Therapy Designation, Bringing New Hope of Survival to NUT Carcinoma Patients